TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03676634

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rBV A/B
Description: Recombinant Botulinum Vaccine A/B, rBV A/B
Study: NCT04722133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HERZUMA+mFOLFOX
Description: Herzuma (Trastuzumab-pkrb) 4mg/kg after 6mg/kg loading D1 5FU 400mg/m2 bolus+2400mg/m2 infusion for 46 hrs D1 Leucovorin 200mg/m2 D1 Oxaliplatin 85mg/m2 D1 every 2 weeks
Study: NCT01703754

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Ad-RTS-hIL-12 and Veledimex
Description: Oral activator ligand with adenoviral vector injection of cancer lesions

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Ad-RTS-hIL-12 and Veledimex
Description: Oral activator ligand with adenoviral vector injection of cancer lesions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifosfamide
Description: Small molecule chemotherapy, IV administration
Study: NCT01953185

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham manual diaphragm release technique
Description: For this group, light touch at the same anatomical points was done without exerting pressure or traction. Positioning and duration were identical to the IG to perform the sham protocol (Licciardone \& Russo, 2006).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The manual diaphragm release technique
Description: To perform the technique the volunteer was placed in supine position with limbs relaxed. Positioned behind the head of the volunteer, the therapist performed manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib, and guiding forearms toward the shoulders of the corresponding side. In the inspiratory phase, the therapist gently pulled the points of contact with both hands, in the direction of the head, yet slightly lateral, accompanying the elevation movement of the ribs. During exhalation, the therapist deepened contact toward the inner costal, maintaining resistance throughout the inspiratory phase. In the breaths following, the therapist sought to gain traction and smooth increase in the deepening of contacts. This maneuver was performed in two sets of ten deep breaths, with a one minute interval between them.
Study: NCT04185857

Intervention type: DRUG
Intervention: canrenone 50-100 mg orally once a day
Description: After two biochemical and clinical evaluations under baseline conditions and after pharmacological washout from diuretics, betablockers, ARBs or ACEI (about 4 weeks) and MRAs (abut 6 weeks), PA patients will be treated with canrenone 50-100 mg orally once a day. After 1 or 2 weeks the dose will be doubled if necessary to control BP and serum potassium.

Intervention type: DRUG
Intervention: olmesartan 10-20 mg orally once a day
Description: After one month of treatment with canrenone the patients will undergo a clinical and biochemical evaluation (FW1) in a manner identical to the two basal evaluations. After, they will continue with a combination therapy with canrenone, at the dose reached, plus olmesartan starting with 10 mg a day for oral administration, a dose that could be doubled, if necessary, to achieve normotension.~At the end of the second month of the double therapy, patients will undergo a biochemical re-evaluation at the Center of Hypertension (FW2) with methods identical to those performed in the two baseline evaluations and after one month of canrenone.
Study: NCT02940457

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum tDCS
Description: Neuropsychological (working memory) training for 30 minutes, 6 sessions tDCS during training with 2 mA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS
Description: Neuropsychological (working memory) training for 30 minutes, 6 sessions tDCS during training with 0 mA
Study: NCT04490954

Intervention type: DEVICE
Group type: OTHER
Intervention: brain biological electrical impedance tomography
Description: Patients diagnosed with brain supratentorial tumors through MRI/CT are evaluated with brain biological electrical impedance tomography. And the brain biological electrical impedance tomography is used to monitor the cerebral edema situation of patients with brain edema

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI/CT
Description: Patients diagnosed with brain supratentorial tumors through MRI/CT

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI/CT
Description: Patients diagnosed with brain supratentorial tumors through MRI/CT
Study: NCT03414918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Hypertensive patients will be exposed to a single oral dose of 150 mg of roxithromycin. A 150-mg oral dose of roxithromycin should yield peak plasma concentrations of 5-12 mcg/mL14, which are higher than the IC50 measured in vitro (0.18-0.53 mcg/mL).
Study: NCT00477373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: depakine chrono
Description: Depakine Chrono 500 mg
Study: NCT04565561

Intervention type: DEVICE
Intervention: Neovas BRS or DCB
Description: All STEMI patients were predilated (including predilated balloon or cutting balloon) before randomization. Thrombus aspiration was determined by the surgeon according to the specific situation.~Sufficient predilation criteria: the following two conditions must be met: A. residual stenosis \< 30%; B. no flow limiting dissection or TIMI grade 2-3.

Intervention type: DEVICE
Intervention: Neovas BRS or DCB
Description: All STEMI patients were predilated (including predilated balloon or cutting balloon) before randomization. Thrombus aspiration was determined by the surgeon according to the specific situation.~Sufficient predilation criteria: the following two conditions must be met: A. residual stenosis \< 30%; B. no flow limiting dissection or TIMI grade 2-3.
Study: NCT01665781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Study: NCT02508714

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orsiro
Description: stents will be implanted in case of significant coronary artery disease

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute Onyx
Description: stents will be implanted in case of significant coronary artery disease based on coronary angiography
Study: NCT02789319

Intervention type: DEVICE
Group type: OTHER
Intervention: Blood Glucose Meter Systems

Intervention type: DEVICE
Group type: OTHER
Intervention: Blood Glucose Meter Systems

Intervention type: DEVICE
Group type: OTHER
Intervention: Blood Glucose Meter Systems

Intervention type: DEVICE
Group type: OTHER
Intervention: Blood Glucose Meter Systems

Intervention type: DEVICE
Group type: OTHER
Intervention: Blood Glucose Meter Systems

Intervention type: DEVICE
Group type: OTHER
Intervention: Blood Glucose Meter Systems

Intervention type: DEVICE
Group type: OTHER
Intervention: Blood Glucose Meter Systems

Intervention type: DEVICE
Group type: OTHER
Intervention: Blood Glucose Meter Systems

Intervention type: DEVICE
Group type: OTHER
Intervention: Blood Glucose Meter Systems

Intervention type: DEVICE
Group type: OTHER
Intervention: Blood Glucose Meter Systems

Intervention type: DEVICE
Group type: OTHER
Intervention: Blood Glucose Meter Systems

Intervention type: DEVICE
Group type: OTHER
Intervention: Blood Glucose Meter Systems

Intervention type: DEVICE
Group type: OTHER
Intervention: Blood Glucose Meter Systems
Study: NCT01907074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholates
Description: Cholates is given intravenously (IV push) and by mouth, once per study visit
Study: NCT04438096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg
Description: One 100 mg pill and two placebo pills (QD) will be orally administered for 12 weeks
Study: NCT02172612

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 1 Education Session
Description: Those included in the intervention group will undergo an educational session with the study pharmacist and one of the licensed prescribers from Sanders-Brown to discuss recommended changes in their treatment plan. If changes in medications are indicated by the pharmacist-prescriber team, and accepted by the patient, new prescriptions will be provided and a letter will be sent to the primary care physicians detailing the changes made and the rationale behind such changes.
Study: NCT02708212

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EGD and colonoscopy
Description: Cold forceps biopsy, cold snare polypectomy, and/or hot snare polypectomy will be performed for stomach and/or colon polyps during EGD and colonoscopy examinations will be performed whenever indicated.
Study: NCT04438096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg
Description: Two 100 mg pills and one placebo pill (QD) will be orally administered for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 mg
Description: Three 100 mg pills (QD) will be orally administered for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three placebo pills (QD) will be orally administered for 12 weeks
Study: NCT01800344

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultra
Description: Ultra
Study: NCT01714973

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ST266
Description: Patients will receive ST266 spray, to half the breast and saline to the other half (blinded) after each of ten consecutive radiation therapy treatments. ST266 and saline will be sprayed onto the breast to deliver 0.01 ml/cm2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ST266
Description: Patients will receive ST266 spray, to half the breast and saline to the other half (blinded) after each of ten consecutive radiation therapy treatments. ST266 and saline will be sprayed onto the breast to deliver 0.01 ml/cm2.
Study: NCT01812343

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise test
Study: NCT04253704

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: IDL lotion
Description: IDL lotion is water-based (\> 80%) with isosorbide di-(linoleate/oleate) (2.0%), caprylic/capric triglycerides (5%), glycerin (3%), glyceryl stearate (2.5%), dimethicone (2.0%), steareth-20 (1.5%), cetyl alcohol (1.0%), and butyrospermum parkii (shea) butter (1.0%).

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Control lotion
Description: Control lotion is water-based (\> 80%) with caprylic/capric triglycerides (5%), glycerin (3%), glyceryl stearate (2.5%), dimethicone (2.0%), steareth-20 (1.5%), cetyl alcohol (1.0%), and butyrospermum parkii (shea) butter (1.0%).
Study: NCT01898312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Randomised controlled trial of Mifepristone and placebo comparator Triobe

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mifepristone
Description: Randomised controlled trial of Mifepristone and placebo comparator Triobe
Study: NCT05700240

Intervention type: DEVICE
Intervention: orthokeratology
Description: rigid contact lenses

Intervention type: DEVICE
Intervention: single-vision spectacle correction
Description: simple wear of spectacle
Study: NCT01883310

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham tDCS + TOCT
Description: Anodal transcranial direct current stimulation will be delivered through 2 sponge electrodes (surface area: 25 cm2) soaked in a saline solution. For the cerebellar transcranial direct current stimulation, the anodal electrode will be centered on the right cerebellar cortex, 3 cm lateral to the inion, and the cathodal electrode will be positioned on the right buccinator muscle. Anodal stimulation intensity will be set at 2 mili Ampere and delivered using a rechargeable batteries direct current stimulator.The sham transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 30 s over the right cerebellar position.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real tDCS +TOCT
Description: Anodal transcranial direct current stimulation will be delivered through 2 sponge electrodes (surface area: 25 cm2) soaked in a saline solution. For the cerebellar transcranial direct current stimulation, the anodal electrode will be centered on the right cerebellar cortex, 3 cm lateral to the inion, and the cathodal electrode will be positioned on the right buccinator muscle. Anodal stimulation intensity will be set at 2 mili Ampere and delivered using a rechargeable batteries direct current stimulator.The real transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 15 minutes over the right cerebellar position.
Study: NCT01172171

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin, N-acetyl-5-methoxytryptamine
Description: The investigators will give the randomized patients 10 ml of 0,1 mg/ml melatonin intracoronarily and 490 ml of 0,1 mg/ml (49 mg) melatonin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline, Natrium chloride
Description: The randomized patients will be given 10 ml of isotonic saline intracoronarily and 490 ml intravenously.
Study: NCT00379938

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAI-VP705 (parvovirus B-19 vaccine)
Description: Recombinant human parvovirus B-19 capsids at dose levels: 25 micrograms of VAI-VP705 with and without MF59 adjuvant and 2.5 micrograms with MF59 adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAI-VP705 (parvovirus B-19 vaccine)
Description: Recombinant human parvovirus B-19 capsids at dose levels: 25 micrograms of VAI-VP705 with and without MF59 adjuvant and 2.5 micrograms with MF59 adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAI-VP705 (parvovirus B-19 vaccine)
Description: Recombinant human parvovirus B-19 capsids at dose levels: 25 micrograms of VAI-VP705 with and without MF59 adjuvant and 2.5 micrograms with MF59 adjuvant.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline control

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF-59
Description: Adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF-59
Description: Adjuvant
Study: NCT00469235

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Avotermin
Description: 10 patients:- 50ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure.~10 Patients:- 200ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Avotermin
Description: 10 patients:- 50ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure.~10 Patients:- 200ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure.
Study: NCT02596880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: 400 mg, included in a combination pill (Sovodak) with 60 mg daclatasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: 60 mg, included in a combination pill (Sovodak) with 400 mg sofosbuvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 1000 mg/day if \<75 kg, 1200 mg/day for \>75 kg. Divided into two daily doses
Study: NCT01426386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 999049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 999049
Study: NCT01007552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Capecitabine and Bevacizumab
Description: Bevacizumab 15 mg/ kg every 3 weeks, starting day 1; Capecitabine 650 mg/m2 bid x 14 days starting day 1, Gemcitabine 1000 mg/m2 days 1 and 8, cycles to be repeated every 21 days.
Study: NCT01426386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 999049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 999049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 999049

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonal - F
Study: NCT00974662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WST11
Description: WST11-mediated VTP will consists of the combination of a single IV administration of WST11 at doses of 5, 7.5 \& 10 mg/kg, using 753 nm laser light at a fixed power of 250 mW/cm and escalating fixed energy dose (200 Joules/cm and 300 Joules/cm) locally delivered to the obstructing tumor through an optical fiber placed, during endoscopy, in the endoscope operating channel with visual control, possibly video-transmission assisted. The fiber illuminating diffusion length is fixed (2 cm).
Study: NCT00785746

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core
Description: We have devised a series of core strength training exercises that can be easily and safely performed under the supervision of trained staff. The exercises will be individualized depending on the participants' ability and health conditions. The majority, but not all, of exercises will be performed on or with exercise balls of different sizes and shapes, round for more advanced persons and oval for more frail persons.
Study: NCT03515980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986231
Description: Intravenous (IV) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986231
Description: Intravenous (IV) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986231
Description: Intravenous (IV) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986231
Description: Intravenous (IV) administration
Study: NCT05450861

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SF DNA extraction composition
Description: the composition of small fragments of DNA from fish

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the scalp conditioning solution without SF DNA extraction composition
Study: NCT03940144

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: the enhanced flow-based hemodynamic parameters of the FloTrac/Vigileo device
Description: Stroke volume variation (SVV)-guided fluid therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the enhanced flow-based hemodynamic parameters of the FloTrac/Vigileo device
Description: Stroke volume variation (SVV)-guided fluid therapy
Study: NCT01225406

Intervention type: DRUG
Intervention: Tenofovir

Intervention type: DRUG
Intervention: Tenofovir
Study: NCT04302181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: 6.5cc of Ropivacaine HCl 0.5%, one time into the stellate ganglion
Study: NCT00946270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-4047
Description: 0.5 mg capsules daily by mouth day 1 through day 28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-4047
Description: 0.5 mg capsules daily by mouth day 1 through day 28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 30 mg by mouth daily during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-4047
Description: 3.0 mg capsules daily by mouth day 1 through 21.
Study: NCT03159442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Powder for inhalation administered via single dose DPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Powder for inhalation administered via single dose DPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Powder for inhalation administered via single dose DPI
Study: NCT06626971

Intervention type: DRUG
Group type: OTHER
Intervention: ARA290
Description: 4 mg subcutaneous injections of ARA290 over an 84 day period
Study: NCT03821974

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wet suction technique
Description: For the wet suction technique, after removing the stylet, the needle was flushed with 2 mL of saline solution to replace the column of air with saline solution. A 10-mL suction syringe, loaded to 5ml negative pressure, was attached in a locked position to the needle after flushing the needle with saline solution. The needle is moved back and forth 20-30 times by applying negative pressure suction within the lesion. Afterwards, the needle is withdrawn from the lesion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wet suction technique
Description: For the wet suction technique, after removing the stylet, the needle was flushed with 2 mL of saline solution to replace the column of air with saline solution. A 10-mL suction syringe, loaded to 5ml negative pressure, was attached in a locked position to the needle after flushing the needle with saline solution. The needle is moved back and forth 20-30 times by applying negative pressure suction within the lesion. Afterwards, the needle is withdrawn from the lesion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dry suction technique
Description: For the dry suction technique, after locating by EUS, the stylet was removed from the needle before performing FNA. A 10-mL syringe, loaded to 5ml negative pressure, was attached in a locked position to the needle. Suction was applied after the lesion was punctured. The needle is moved back and forth 20-30 times by applying negative pressure suction within the lesion. Afterwards, the needle is withdrawn from the lesion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dry suction technique
Description: For the dry suction technique, after locating by EUS, the stylet was removed from the needle before performing FNA. A 10-mL syringe, loaded to 5ml negative pressure, was attached in a locked position to the needle. Suction was applied after the lesion was punctured. The needle is moved back and forth 20-30 times by applying negative pressure suction within the lesion. Afterwards, the needle is withdrawn from the lesion.
Study: NCT02722421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel
Description: Increased dose levonorgestrel implant plus efavirenz-based antiretroviral therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Participants will receive efavirenz-based ART as part of standard of care